Press releasesMarch 4th, 2019 08:00
Immunovia provides an update on the optimization work to meet the expected performance for commercialization of IMMray™ PanCan-d
Immunovia has today secured blood samples that best conforms to real-life, commercial conditions, which will form the basis for the commercial test model study.
“We remain confident that the steps taken to obtain blood samples that best match the samples that will eventually be used by clinicians in the diagnosis process is the key element for the final adjustments before our commercial launch,” concluded Mats Grahn, CEO.
A telephone conference is scheduled on March 4, 2019, 10.30 CET to answer questions and provide additional details.
Participant dial in numbers:
On the Immunova website under Investors/Audio Gallery (https://immunovia.com/investors/audio-gallery/) there will be an MP3 file for those who want to listen to the conference call later, the file is available within two hours of the end of the conference call.
For more information, please contact:
Director of Investor Relations
Tel: +46 7 93 486 277
This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 CET on March 4, 2019.
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
About Pancreatic Cancer
Pancreatic Cancer is one of the most deadly and difficult to detect cancers, as the signs and symptoms are diffuse and similar to other diseases. There are more than 40,000 deaths and over 50,000 new cases diagnosed each year in the U.S. alone, and the five-year survival rate for pancreatic cancer is currently 5-8 %. It is predicted to become the second leading cause of cancer death by 2020. However, because resection is more successful in stage I/II, early diagnosis can significantly improve pancreatic cancer patients’ 5-year survival rates from 5-8 % to up to 49%.